The effect of dose on local control of XXXX .

@entity1 @entity263 @entity5
Three patterns of care outcome surveys in @entity263 totalling 1516 @entity1 had been combined and analyzed for the effect of dose on infield recurrence. There are significant dose effects observed in the overall data (1516 @entity1 , p = .003), @entity5 (725 @entity1 , p = .004) and @entity5 (624 @entity1 , p = .059). No dose effect was observed for @entity5 (168 @entity1 , p = .217) within the dose range observed (5500 cGy to greater than 7000 cGy). For @entity1 with Stage B @entity5 one may conclude that dose between 6000 cGy and 6999 cGy is appropriate. @entity1 treated to less than 6000 cGy show a highly significant increase in local failure. @entity1 treated to greater than 7000 cGy do not show a demonstrable improvement in local control, but do show an increase in complications. @entity1 with Stage C @entity5 appear to require dose that is equal or greater than 7000 cGy to obtain the best local control, and the potential increased morbidity of these high doses appears to be justified in this stage of the disease. @entity1 who have been given hormonal therapy more than 1 month prior to radiation therapy show an increase in local failure rate for all stages of @entity5 . This is presumed to be the selection of poor risk @entity1 for adjuvant hormonal treatment or by referring non-responding hormone treated @entity1 for radiation therapy. Histologic grade exerts a major influence on local failure for @entity1 with Stage C disease (p = less than .001), identifying an important stratification point for prospective clinical trials and a sub-group for which it is important to develop strategies for improving local control. The policy of treating all stages of @entity263 with the same dose is not supported by these data.
